Augmented methamphetamine-induced overflow of striatal dopamine 1 day after GDNF administration

Brain Research

Volumn 827, Issue 1-2, 1999, Pages 104-112

  Cass, Wayne A ^a   Walker, Doriann J ^a   Manning, Michael W ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Dopamine; GDNF; In vivo microdialysis; Methamphetamine; Neurotrophic factor; Striatum; Substantia nigra

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HOMOVANILLIC ACID; METHAMPHETAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINE RELEASE; HORMONE ACTION; MALE; MICRODIALYSIS; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HOMOVANILLIC ACID; MALE; METHAMPHETAMINE; MICRODIALYSIS; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; RATS; RATS, INBRED F344; SUBSTANTIA NIGRA;

EID: 0033535780     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01314-1     Document Type: Article

References (41)

1. Abekawa T., Ohmori T., Koyama T. Effects of repeated administration of a high dose of methamphetamine on dopamine and glutamate release in the rat striatum and nucleus accumbens. Brain Res. 643:1994;276-281.
2. Baldwin H.A., Colado M.I., Murray T.K., De Souza R.J., Green A.R. Striatal dopamine release in vivo following neurotoxic doses of methamphetamine and effect of the neuroprotective drugs, chlormethiazole and dizocilpine. Br. J. Pharmacol. 108:1993;590-596.
3. Cadet J.L., Sheng P., Ali S., Rothman R., Carlson E., Epstein C. Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J. Neurochem. 62:1994;380-383.
4. Cappon G.D., Broening H.W., Pu C., Morford L., Vorhees C.V. Alpha-phenyl-N-tert-butyl nitrone attenuates methamphetamine-induced depletion of striatal dopamine without altering hyperthermia. Synapse. 24:1996;173-181.
5. Cass W.A. GDNF selectively protects dopamine neurons over serotonin neurons against the neurotoxic effects of methamphetamine. J. Neurosci. 16:1996;8132-8139.
6. Cass W.A. Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of amphetamine. J. Pharmacol. Exp. Ther. 280:1997;105-113.
7. W.A. Cass, C.M. Kearns, D.M. Gash, Protective and regenerative properties of GDNF in the central nervous system, in: M.P. Mattson (Ed.), Neuroprotective Signal Transduction, Humana Press, Totowa, 1998, pp. 145-161.
8. Chao C.C., Lee E.H.Y. Alterations of antioxidant enzyme systems and behavior in rats by intrastriatal injection of glial cell line-derived neurotrophic factor. Soc. Neurosci. Abstr. 24:1998;42.
9. Cubells J.F., Rayport S., Rajendran G., Sulzer D. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 14:1994;2260-2271.
10. Cumming P., Brown E., Damsma G., Fibiger H. Formation and clearance of interstitial metabolites of dopamine and serotonin in the rat striatum: an in vivo microdialysis study. J. Neurochem. 59:1992;1905-1914.
11. Emerich D.F., Plone M., Francis J., Frydel B.R., Winn S.R., Lindner M.D. Alleviation of behavioral deficits in aged rodents following implantation of encapsulated GDNF-producing fibroblasts. Brain Res. 736:1996;99-110.
12. Gash D.M., Zhang Z., Cass W.A., Ovadia A., Simmerman L., Martin D., Russell D., Collins F., Hoffer B.J., Gerhardt G.A. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys. J. Comp. Neurol. 363:1995;345-358.
13. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., Gerhardt G.A. Functional recovery in GDNF-treated Parkinsonian monkeys. Nature. 380:1996;252-255.
14. J.W. Gibb, G.R. Hanson, M. Johnson, Neurochemical mechanisms of toxicity, in: A.K. Cho, D.S. Segal (Eds.), Amphetamine and its Analogs: Pharmacology, Toxicology and Abuse, Academic Press, San Diego, 1994, pp. 269-295.
15. Giovanni A., Liang L.P., Hastings T.G., Zigmond M.J. Estimating hydroxy radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine. J. Neurochem. 64:1995;1819-1825.
16. Glick S.D., Dong N., Keller R.W. Jr., Carlson J.N. Estimating extracellular concentrations of dopamine and 3,4-dihydroxyphenylacetic acid in nucleus accumbens and striatum using microdialysis: relationships between in vitro and in vivo recoveries. J. Neurochem. 62:1994;2017-2021.
17. Hebert M.A., Gerhardt G.A. Behavioral and neurochemical effects of intranigral administration of glial cell line-derived neurotrophic factor on aged Fischer 344 rats. J. Pharmacol. Exp. Ther. 282:1997;760-768.
18. Hebert M.A., van Horne C.G., Hoffer B.J., Gerhardt G.A. Functional effects of GDNF in normal rat striatum: presynaptic studies using in vivo electrochemistry and microdialysis. J. Pharmacol. Exp. Ther. 279:1996;1181-1190.
19. Hirata H., Ladenheim B., Carlson E., Epstein C., Cadet J.L. Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: attenuation in CuZn-superoxide dismutase transgenic mice. Brain Res. 714:1996;95-103.
20. Hoffer B.J., Hoffman A., Bowenkamp K., Huettl P., Hudson J., Martin D., Lin L.-F.H., Gerhardt G.A. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett. 182:1994;107-111.
21. Holson R.R., Bowyer J.F., Clausing P., Gough B. Methamphetamine-stimulated striatal dopamine release declines rapidly over time following microdialysis probe insertion. Brain Res. 739:1996;301-307.
22. Hudson J., Granholm A.-C., Gerhardt G., Henry M.A., Hoffman A., Biddle P., Leela N.S., Mackerlova L., Lile J.D., Collins F., Hoffer B.J. Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res. Bull. 36:1995;425-432.
23. Kearns C.M., Cass W.A., Smoot K., Kryscio R., Gash D.M. GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis. J. Neurosci. 17:1997;7111-7118.
24. Kojima H., Abiru Y., Sakajiri K., Watabe K., Ohishi N., Takamori M., Hatanaka H., Yagi K. Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain. Biochem. Biophys. Res. Commun. 238:1997;569-573.
25. Lapchak P.A., Gash D.M., Collins F., Hilt D., Miller P.J., Araujo D.M. Pharmacological activities of glial cell line-derived neurotrophic factor (GDNF): preclinical development and application to the treatment of Parkinson's disease. Exp. Neurol. 145:1997;309-321.
26. Lapchak P.A., Miller P.J., Jiao S. Glial cell line-derived neurotrophic factor induces the dopaminergic and cholinergic phenotype and increases locomotor activity in aged Fischer 344 rats. Neuroscience. 77:1997;745-752.
27. Lin L.-F.H., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 260:1993;1130-1132.
28. Martin D., Miller G., Cullen T., Fischer N., Dix D., Russell D. Intranigral or intrastriatal injections of GDNF: effects on monoamine levels and behavior in rats. Eur. J. Pharmacol. 317:1996;247-256.
29. Martin D., Miller G., Fischer N., Dix D., Cullen T., Russell D. Glial cell line-derived neurotrophic factor: the lateral cerebral ventricle as a site of administration for stimulation of the substantia nigra dopamine system in rats. Eur. J. Neurosci. 8:1996;1249-1255.
30. Moghaddam B., Bunney B.S. Ionic composition of microdialysis perfusing solution alters the pharmacological responsiveness and basal outflow of striatal dopamine. J. Neurochem. 53:1989;652-654.
31. Nielsen E.B. Rapid decline of stereotyped behavior in rats during constant one week administration of amphetamine via implanted ALZET osmotic minipumps. Pharmacol. Biochem. Behav. 15:1981;161-165.
32. O'Dell S.J., Weihmuller F.B., Marshall J.F. Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity. Brain Res. 564:1991;256-260.
33. Pothos E.N., Davila V., Sulzer D. Presynaptic recording of quanta from midbrain dopamine neurons and modulation of the quantal size. J. Neurosci. 18:1998;4106-4118.
34. Rosenblad C., Martinez-Serrano A., Björklund A. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience. 82:1998;129-137.
35. Seiden L.S., Sabol K.E., Ricaurte G.A. Amphetamine: effects on catecholamine systems and behavior. Annu. Rev. Pharmacol. Toxicol. 32:1993;639-677.
36. Stephans S.E., Yamamoto B.K. Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse. 17:1994;203-209.
37. Sullivan A.M., Opacka-Juffry J., Blunt S.B. Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo. Eur. J. Neurosci. 10:1998;57-63.
38. Tomac A., Lindqvist E., Lin L.-F.H., Ogren S.O., Young D., Hoffer B.J., Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature. 373:1995;335-339.
39. Tomac A., Widenfalk J., Lin L.-F.H., Kohno T., Ebendal T., Hoffer B.J., Olson L. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc. Natl. Acad. Sci. USA. 92:1995;8274-8278.
40. Weihmuller F.B., O'Dell S.J., Marshall J.F. L-DOPA pretreatment potentiates striatal dopamine overflow and produces dopamine terminal injury after a single methamphetamine injection. Brain Res. 623:1993;303-307.
41. Winkler C., Sauer H., Lee C.S., Björklund A. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 16:1996;7206-7215.